Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1996-09-20
1999-09-28
Spivack, Phyllis G.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
514249, 514317, 514428, A61K 3140, A61K 31445, A61K 31495, A61K 3155
Patent
active
059589191
ABSTRACT:
Methods for treating the very early (presymptomatic) stages of Alzheimer's disease are disclosed, wherein NMDA antagonist drugs are administered to protect NMDA receptors against neuronal damage. Since NMDA antagonists may cause a condition known as NMDA receptor hypofunction (NR/hypo) that triggers neurotoxic side effects, they may be co-administered with, or have inherent activity as, "safener" drugs to prevent toxic side effects. The patient's status must be monitored, so that any NMDA antagonist drugs can be discontinued if a condition of NR/hypo arises. Otherwise, the NMDA antagonist drugs can worsen and accelerate the damage caused by the disease.
REFERENCES:
patent: 5034400 (1991-07-01), Olney et al.
patent: 5547963 (1996-08-01), Poindron et al.
Corey-Bloom, J., et al, "Adjunctive therapy in patients with Alzheimer's disease: A practical approach," Drugs Aging 7 : 79-87 (1995).
Gong, C.X., et al, "Inhibition of protein phosphatase-2B (calcineurin) activity towards Alzheimer abnormally phosphorylated tau by neuroleptics," Brain Res 741: 95-102 (1996).
Grossberg, G.T., et al, "The older patient with psychotic symptoms," Psychiatr Serv 46: 55-9 (1995).
Niizato, K., et al, "Long-term antipsychotic medication of schizophrenics does not promote the development of Alzheimers's disease brain pathology," J Neurol Sci 138: 167-7 (1996).
Rabins, P.V., "Developing treatment guidelines for Alzheimer's disease and other dementias," J Clin Psychiatry 57 Suppl.14: 37-38 (1996).
Schneider, L.S., "New therapeutic approaches to Alzheimer's disease," J Clin Psychiatry 57 Suppl. 14: 39-44 (1996).
Siegal, A., et al, "Discussion: Clinical developments in Alzheimer'disease," J Clin Psychiatry 57 Suppl. 14 : 39-44 (1996).
Sunderland, T., "Treatment of the elderly suffering from psychosis and dementia," J Clin Psychiatry 57 Suppl. 9: 53-6 (1996).
Tueth, M.J., "How to manage depression and psychosis in Alzheimer's disease," Geriatrics 50: 43-6, 49 (1995).
Zayas, E.M., et al, "Treating the agitated Alzheimer patient," J Clin Psychiatry 57 Suppl. 7: 46-54 (1996).
Beal, M.F., "Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses?" Ann Neurol 31: 119-30 (1992).
Bowen, D.M., "Treatment of Alzheimer's disease. Molecular pathology versus neurotransmitter-based therapy," Br J Psychiatry 157: 327-30 (1990).
Cotman, C.W., et al, "Plasticity of excitatory amino acid receptors: implications for aging and Alzheimer's disease," Prog Brain Res 86: 55-61 (1990).
Fonnum, F., et al, "Role of glutamate and glutamate receptors in memory function and Alzheimer's disease," Annals New York Acad Sci 757: 475-86 (1995).
Francis, P.T., et al, "A glycine site as therapeutic target," Annals New York Acad Sci 640 : 184-8 (1991).
Herting, R.L., "Milacemide and other drugs active at glutamate NMDA receptors as potential treatment for dementia, " Annals New York Acad Sci 640: 237-40 (1991).
Koh, J.Y. et al, "Beta-amyloid protein increases the vulnerability of cultured cortical neurons to excitotoxic damage," Brain Res 533: 315-20 (1990).
Kornhuber, J., et al, "Psychotogenicity and N-methyl-D-aspartate receptor antagonism: implications for neuroprotective pharmacotherapy," Biol Psychiatry 41: 135-44 (1997).
Lawlor, B.A., et al, "Does modulation of glutamatergic function represent a viable therapeutic strategy in Alzheimer's disease?" Biol Psychiatry 31: 337-50 (1992).
Scheuer, K., et al, "Cortical NMDA receptor properties and membrane fluidity are altered in Alzheimer'disease," Dementia 7 : 210-4 (1996).
Ulas, J., et al, "NMDA receptor complex in the hippocampus of elderly, normal individuals and those with Alzheimer's disease," Neuroscience 49: 45-61 (1992).
Abramowicz, M., "Donepezil (Aricept) for Alzheimer's Disease," The Medical Letter 39: 53-54 (1997).
Bryson, H.M., et al, "Donepezil," Drugs and Aging 10: 234-241 (1997).
Ditzler, K., "Efficacy and Tolerability of Memantine in Patients with Dementia Syndrome," Arzneim.-Forsch. /Drug Res. 41(II) : 773-780 (1991).
Ellison, G., "The N-methyl-D-aspartate antagonists phencyclidine, ketamine and dizocilpine as both behavioral and anatomical models of the dementias," Brain Research Reviews 20: 250-267 (1995).
Gilman, S., "Alzheimer's Disease," Perspectives in Biology and Medicine 40: 230-245 (1997).
Gortelmeyer, R., et al, "Memantine in the Treatment of Mild to Moderate Dementia Syndrome," Arzneim.-Forsch./Drug Res. 42(II) : 904-913 (1992).
Khachaturian, Z.S., "Scientific Opportuinties for Developing Treatments for Alzheimer's Disease: Proceedings of Research Planning Workshop 1," Neurobiology of Aging 15, Suppl. 2: S11-S15 (1994).
Marx, J., "Searching for Drugs That Combat Alzheimer's," Science 273: 50-53 (1996).
Mattson, M.P., "Degenerative and Protective Signaling Mechanisims in the Neurofibrillary Pathology of AD," Neurobiology of Aging 16 : 447-457 (1995).
Olney, J.W., et al, "NMDA antagonist neurotoxicity: Mechanism and prevention," Science 254: 1515-1518 (1991).
Olney, J.W., et al, "Excitatory transmitter neurotoxicity and Alzheimer's disease," pp. 293-298 in Alzheimer's Disease:Therapeutic Strategies (Giacobini & Becker, eds., Birkhauser Publ., Boston, 1994).
Olney, J.W., et al, "NMDA receptor hypofunction, excitotoxicity, and Alzheimer's disease," Neurobiology of Aging 16: 459-461 (1995).
Schehr, R.S., "Therapeutic approaches to Alzheimer's disease," Bio/Technology 12: 140-144 (1994).
Selkoe, D.J., "Alzheimer's disease: Genotypes, phenotype, and treatments," Science 275: 630-631 (1997).
Farber Nuri B.
Olney John W.
Kelly Patrick D.
Spivack Phyllis G.
Washington University
LandOfFree
Treatment of presymptomatic alzheimer's disease to prevent neuro does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of presymptomatic alzheimer's disease to prevent neuro, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of presymptomatic alzheimer's disease to prevent neuro will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-703426